Pharmaceutical Industry

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.